D-Pharm Ltd. has recruited the first patient for its Phase II trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a first-in-class cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in patients with acute pancreatitis. The study is enrolling 30 patients to be treated, twice daily for two days, with e...